Cardiology
Nuvelo completes enrollment in Phase III trial of alfimeprase in acute arterial occlusion
Published in Medical Letter on the CDC and FDA, October 8th, 2006
The Phase III trial, known as NAPA-2 (Novel Arterial Perfusion with Alfimeprase-2), is the first of two multinational trials in the Phase III alfimeprase program for acute PAO. This randomized, double-blind study compared the efficacy and safety of 0.3 mg/kg of alfimeprase versus placebo in approximately 300 patients in over 100 centers worldwide.
The study's primary endpoint is avoidance of open vascular surgery within 30 days of treatment. Open vascular surgery...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Antibacterial Agents
Intrapartum antibiotics prevent Escherichia coli infection only for term infants - Cancer Therapy
Antitumor responses are enhanced by B-cell depletion via decrease in IL-10 production - Cardiovascular Disease
Inhibition of rapamycin target modulates adhesion molecule expression - HIV/AIDS Epidemiology
HIV/AIDS epidemiology of adolescents and young adults in U.S. is reported - Rotavirus Vaccine
Restricting rotavirus vaccination schedule did not decrease risk of intussusception - Alcohol Use
Adolescent alcohol abuse and dependence are affected by parental factors - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
